-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision. The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...
More »SEARCH RESULT
Govt uses special powers to slash cancer drug price by 97%-Rupali Mukherjee
In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%. In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's Natco Pharma to sell generic drug Nexavar,...
More »Natco Pharma bags licence to sell Bayer's cancer drug Nexavar
-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision. The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...
More »No Walmart, Please by Rajindar Sachar
If the combined Opposition had sat down for weeks so as to find an issue to embarrass the UPA Government and make it a laughing stock before the whole country, they could not have thought of a better issue than the free gift presented to it by the UPA Government by initially insisting that it had irrevocably decided to allow the entry of multi-brand retail leader superstores like Walmart, USA...
More »Prices of 348 essential drugs to be controlled
-The Times of India The Centre on Thursday responded to the Supreme Court's concern over spiralling prices of essential medicines and promised to make all-out efforts to put under strict price control regime all the 348 drugs included in the National List of Essential Medicines (NLEM), 2011. A bench comprising Justices G S Singhvi and S J Mukhopadhaya had, in the last hearing, expressed concern over the shrinking list of medicines under...
More »